The outlook of companies tied to flagship drugs like Viagra presents a nuanced investment picture. While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial profits , the expiry in key territories has introduced considerable uncertainty . Investors are now facing the consequences of lower-cost alternat